×
About 4,270 results

ALLMedicine™ Pheochromocytoma Center

Research & Reviews  1,558 results

A case of juvenile-onset pheochromocytoma with KIF1B p.V1529M germline mutation.
https://doi.org/10.1507/endocrj.EJ21-0475
Endocrine Journal; Nezu M, Hirotsu Y et. al.

Jan 21st, 2022 - In 2008, a familial noradrenergic pheochromocytoma (PCC) with a KIF1B germline mutation in exon 41 was reported in a 24-year-old female proband and her family. However, in 2020, the same research group reported that the cause of PCC in this family...

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogen...
https://clinicaltrials.gov/ct2/show/NCT03165721

Jan 19th, 2022 - Background Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH) complex or fumarate hydratase (FH), has been identified as a mechanism of tumorigenesis in subsets of gastrointestinal stromal tumor (GIST), pheochromocytoma a...

Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multi-center...
https://doi.org/10.1210/clinem/dgac019
The Journal of Clinical Endocrinology and Metabolism; Davidoff DF, Benn DE et. al.

Jan 18th, 2022 - Carriers of succinate dehydrogenase type B (SDHB) pathogenic variants (PV) are at risk of pheochromocytoma and paraganglioma (PPGL) from a young age. It is widely recommended carriers enter a surveillance program to detect tumors but there are lim...

Development of a radiomics model to diagnose pheochromocytoma preoperatively: a multice...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760711
Journal of Translational Medicine; Kong J, Zheng J et. al.

Jan 17th, 2022 - Preoperative diagnosis of pheochromocytoma (PHEO) accurately impacts preoperative preparation and surgical outcome in PHEO patients. Highly reliable model to diagnose PHEO is lacking. We aimed to develop a magnetic resonance imaging (MRI)-based ra...

see more →

Guidelines  3 results

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance a...
https://doi.org/10.1097/MPA.0000000000001792
Pancreas Fishbein L, Del Rivero J et. al.

May 4th, 2021 - This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management and surveillance of metastatic and unresectable pheochromocytoma and paraganglioma held on October 2 and 3, 2019. The p...

Care of adults with neurofibromatosis type 1: a clinical practice resource of the Ameri...
https://doi.org/10.1038/gim.2018.28
Genetics in Medicine : Official Journal of the American C... Stewart DR, Korf BR et. al.

Jul 15th, 2018 - This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessaril...

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419007
Pancreas Chen H, Sippel RS et. al.

Jul 29th, 2010 - Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal chromaffin cells or similar cells in extra-adrenal sympathetic and parasympathetic para...

see more →

Drugs  49 results see all →

Clinicaltrials.gov  28 results

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogen...
https://clinicaltrials.gov/ct2/show/NCT03165721

Jan 19th, 2022 - Background Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH) complex or fumarate hydratase (FH), has been identified as a mechanism of tumorigenesis in subsets of gastrointestinal stromal tumor (GIST), pheochromocytoma a...

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
https://clinicaltrials.gov/ct2/show/NCT04394858

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone....

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
https://clinicaltrials.gov/ct2/show/NCT04924075

Jan 13th, 2022 - This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the obje...

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

Jan 3rd, 2022 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
https://clinicaltrials.gov/ct2/show/NCT00843037

Nov 30th, 2021 - This study will be a single arm, open-label, phase II trial of sunitinib in patients with metastatic or locally advanced malignant paraganglioma or phaeochromocytoma. Oral sunitinib (50 mg) will be administered to all patients daily for the first ...

see more →

News  61 results

Pheochromocytoma: An Incidental Finding in an Asymptomatic Older Adult With Renal Oncocytoma
https://www.mdedge.com/fedprac/article/249919/nephrology/pheochromocytoma-incidental-finding-asymptomatic-older-adult-renal
Maryam Bushra Ahmed, Zayan Ahmed Sami et. al.

Dec 15th, 2021 - Pheochromocytoma is a rare catecholamine-secreting tumor of chromaffin cells of the adrenal medulla or sympathetic ganglia, occurring in about 0. 2 to 0.

Influx of Therapies in NETs Prompts Questions Over Combinations and Sequencing
https://www.onclive.com/view/influx-of-therapies-in-nets-prompts-questions-over-combinations-and-sequencing

Nov 19th, 2021 - Tyrosine kinase inhibitors (TKIs), hypoxia-inducible factor 2α (HIF-2α) inhibitors, and peptide receptor radiotherapy are generating excitement in the field of neuroendocrine tumors (NETs), explained Diane Reidy-Lagunes, MD. However, until more de...

Neuroendocrine Tumors Clinical Practice Guidelines (NCCN, 2021)
https://www.medscape.com/viewarticle/959868

Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...

Diagnosis and Initial Treatment of MTC
https://www.onclive.com/view/diagnosis-and-initial-treatment-of-mtc

Apr 2nd, 2021 - For High-Definition, Click Medullary thyroid cancer is commonly diagnosed following the discovery of a mass in the neck, which may cause discomfort, explains Gary L. Clayman, DMD, MD. Once diagnosed, patients should receive genetic counseling, s...

FDA Approvals in Melanoma and Breast Cancer, Priority Reviews in Prostate Cancer and More
https://www.onclive.com/view/fda-approvals-in-melanoma-and-breast-cancer-priority-reviews-in-prostate-cancer-and-more

Apr 2nd, 2021 - Today- FDA approvals in melanoma and breast cancer, priority review designations in prostate cancer, melanoma, Hodgkin lymphoma, and neuroendocrine tumors, and breakthrough therapy designations in breast cancer and renal cell carcinoma. Welc...

see more →

Patient Education  9 results see all →